Thrombocythemia, Essential
"Thrombocythemia, Essential" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A clinical syndrome characterized by repeated spontaneous hemorrhages and a remarkable increase in the number of circulating platelets.
| Descriptor ID |
D013920
|
| MeSH Number(s) |
C15.378.100.832 C15.378.140.860.800 C15.378.190.636.860.800 C15.378.463.825
|
| Concept/Terms |
Thrombocythemia, Essential- Thrombocythemia, Essential
- Essential Thrombocythemia
- Essential Thrombocythemias
- Thrombocythemias, Essential
- Thrombocythemia, Hemorrhagic
- Primary Thrombocythemia
- Thrombocythemia, Primary
- Primary Thrombocythemias
- Thrombocythemias, Primary
- Thrombocytosis, Primary
- Primary Thrombocytoses
- Primary Thrombocytosis
- Thrombocytoses, Primary
- Hemorrhagic Thrombocythemia
- Hemorrhagic Thrombocythemias
- Thrombocythemias, Hemorrhagic
- Thrombocythemia, Idiopathic
- Idiopathic Thrombocythemia
- Idiopathic Thrombocythemias
- Thrombocythemias, Idiopathic
Thrombocytosis, Autosomal Dominant- Thrombocytosis, Autosomal Dominant
- Autosomal Dominant Thrombocytoses
- Autosomal Dominant Thrombocytosis
- Dominant Thrombocytoses, Autosomal
- Dominant Thrombocytosis, Autosomal
- Thrombocytoses, Autosomal Dominant
|
Below are MeSH descriptors whose meaning is more general than "Thrombocythemia, Essential".
Below are MeSH descriptors whose meaning is more specific than "Thrombocythemia, Essential".
This graph shows the total number of publications written about "Thrombocythemia, Essential" by people in this website by year, and whether "Thrombocythemia, Essential" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 1 | 0 | 1 |
| 1998 | 1 | 0 | 1 |
| 2002 | 2 | 0 | 2 |
| 2004 | 1 | 0 | 1 |
| 2005 | 1 | 1 | 2 |
| 2006 | 1 | 0 | 1 |
| 2007 | 2 | 4 | 6 |
| 2008 | 1 | 0 | 1 |
| 2009 | 4 | 2 | 6 |
| 2010 | 2 | 0 | 2 |
| 2011 | 0 | 2 | 2 |
| 2012 | 1 | 0 | 1 |
| 2013 | 5 | 2 | 7 |
| 2014 | 3 | 1 | 4 |
| 2015 | 6 | 1 | 7 |
| 2016 | 4 | 2 | 6 |
| 2017 | 10 | 3 | 13 |
| 2018 | 3 | 0 | 3 |
| 2019 | 3 | 1 | 4 |
| 2020 | 2 | 0 | 2 |
| 2021 | 4 | 0 | 4 |
| 2022 | 7 | 0 | 7 |
| 2023 | 4 | 0 | 4 |
To return to the timeline,
click here.
Below are the most recent publications written about "Thrombocythemia, Essential" by people in Profiles.
-
Iron is a modifier of the phenotypes of JAK2-mutant myeloproliferative neoplasms. Blood. 2023 04 27; 141(17):2127-2140.
-
Genetic basis and molecular profiling in myeloproliferative neoplasms. Blood. 2023 04 20; 141(16):1909-1921.
-
Downregulated KLF2 in polycythemia vera and essential thrombocythemia induces prothrombotic gene expression. Blood Adv. 2023 03 14; 7(5):712-717.
-
A review of essential thrombocythemia and its complications. Clin Adv Hematol Oncol. 2023 Feb; 21(2):76-84.
-
Real-world study of children and young adults with myeloproliferative neoplasms: identifying risks and unmet needs. Blood Adv. 2022 09 13; 6(17):5171-5183.
-
Myeloproliferative Neoplasms, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2022 09; 20(9):1033-1062.
-
Advances in Risk Stratification and Treatment of Polycythemia Vera and Essential Thrombocythemia. Curr Hematol Malig Rep. 2022 10; 17(5):155-169.
-
SURPASS-ET: phase III study of ropeginterferon alfa-2b versus anagrelide as second-line therapy in essential thrombocythemia. Future Oncol. 2022 Sep; 18(27):2999-3009.
-
Essential thrombocythemia complicating hemoglobin SC disease and presenting with priapism. Blood. 2022 04 07; 139(14):2258.
-
Thrombotic events and mortality risk in patients with newly diagnosed polycythemia vera or essential thrombocythemia. Leuk Res. 2022 04; 115:106809.